Rapport d’analyse de la taille, de la part et des tendances du marché mondial des produits radiopharmaceutiques – Aperçu et prévisions de l’industrie jusqu’en 2031

Analyse du marché des produits radiopharmaceutiques

Le marché des produits radiopharmaceutiques connaît une croissance significative, tirée par les progrès de la médecine nucléaire et par l'augmentation des applications dans les secteurs diagnostique et thérapeutique. Les progrès des thérapies ciblées, notamment en oncologie, ont conduit à une augmentation de l'utilisation des produits radiopharmaceutiques pour la médecine personnalisée. Par exemple, l'approbation par la FDA de nouvelles thérapies à base de radioligands a ouvert la voie à des options de traitement plus efficaces, adaptées à des profils de patients spécifiques. En outre, les avancées technologiques telles que l'amélioration des techniques d'imagerie et l'intégration de l'intelligence artificielle améliorent la précision et l'efficacité des applications radiopharmaceutiques. La prévalence croissante des maladies chroniques, notamment du cancer et des troubles cardiovasculaires, stimule encore davantage la demande du marché, car les prestataires de soins de santé adoptent de plus en plus les produits radiopharmaceutiques pour le diagnostic et le traitement précoces. Les partenariats et les collaborations entre acteurs clés, tels que le récent accord entre Bayer et PanTera pour l'actinium-225, stimulent également l'innovation dans le secteur. Avec l'accent croissant mis sur la médecine de précision et l'expansion des activités de recherche, le marché des produits radiopharmaceutiques est sur le point de connaître une croissance substantielle dans les années à venir, le positionnant comme un domaine essentiel des soins de santé modernes.

Taille du marché des produits radiopharmaceutiques

Français La taille du marché mondial des produits radiopharmaceutiques était évaluée à 15,31 milliards USD en 2023 et devrait atteindre 25,33 milliards USD d'ici 2031, avec un TCAC de 6,50 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Tendances du marché des produits radiopharmaceutiques

« Adoption croissante du théranostic »

The radiopharmaceuticals market is experiencing significant growth driven by advancements in nuclear medicine and increasing applications in both diagnostic and therapeutic sectors. One prominent trend in the radiopharmaceuticals market is the rising adoption of theranostics, which combines therapeutic and diagnostic capabilities in a single approach. Such innovative strategy allows for personalized medicine, enabling healthcare providers to tailor treatments based on individual patient responses. For instance, the use of radioligand therapies, such as Lutetium-177 (Lu-177) for treating neuroendocrine tumors, exemplifies this trend, as it helps in imaging the tumors and delivers targeted radiation therapy. Companies such as Novartis, with its acquisition of Endocyte, are leading the way in developing theranostic agents that enhance treatment efficacy while minimizing side effects. This shift toward theranostics is expected to significantly boost the radiopharmaceuticals market, as it improves patient outcomes and fosters a more tailored approach to cancer treatment. The growing emphasis on precision medicine and the integration of advanced imaging techniques further support this trend, making theranostics a key driver in the evolution of the radiopharmaceutical landscape.

Report Scope and Radiopharmaceuticals Market Segmentation       

Radiopharmaceuticals Market Definition

Radiopharmaceuticals are radioactive compounds used in medical imaging and therapy. These substances are designed to diagnose or treat diseases, particularly cancer, by emitting radiation that can be detected by imaging devices or by delivering targeted therapeutic radiation to specific tissues. Radiopharmaceuticals consist of a radioactive isotope linked to a biologically active molecule, which allows for precise targeting within the body. Radiopharmaceuticals ability to combine diagnostic and therapeutic functions has led to the growing field of theranostics, enhancing personalized medicine in oncology and other areas.

Radiopharmaceuticals Market Dynamics

Drivers

• Increasing Incidence of Cancer

The increasing incidence of cancer worldwide is a significant driver of the radiopharmaceuticals market, as these compounds provide innovative approaches for both diagnosis and treatment. According to the World Health Organization (WHO), the number of new cancer cases is expected to rise to 27.5 million by 2040, representing a substantial increase from 19.3 million cases in 2020. This alarming trend underscores the urgent need for effective therapeutic solutions, such as radiopharmaceuticals, which target cancer cells with high precision while minimizing damage to surrounding healthy tissue. For instance, the use of radioligand therapy, a type of targeted radiopharmaceutical treatment, has shown promising results in managing prostate cancer and neuroendocrine tumors, significantly improving patient outcomes. As healthcare systems continue to seek advanced methods for cancer management, the demand for radiopharmaceuticals is likely to expand, making it a critical market driver in the ongoing fight against cancer.

• Expanding Application Across Various Medical Fields

The expanding applications of radiopharmaceuticals across various medical fields, including cardiology, neurology, and infectious diseases, significantly enhance their market potential and drive demand in multiple healthcare segments. For instance, in cardiology, radiopharmaceuticals such as Technetium-99m (Tc-99m) are widely used for single-photon emission computed tomography (SPECT) imaging, providing critical information about myocardial perfusion and function.  In neurology, the application of radiopharmaceuticals in diagnosing conditions such as Alzheimer's disease and Parkinson's disease is becoming increasingly prominent. For instance, PET scans utilizing Fluorodeoxyglucose (FDG) can reveal metabolic activity in the brain, aiding in the early detection of neurodegenerative disorders. This broadening scope of applications widens the market potential for radiopharmaceuticals and also solidifies their role as essential tools in modern medicine, contributing to their sustained demand across various healthcare sectors, thereby driving market growth.

Opportunities

• Increasing Advancements in Imaging Techniques

Advancements in imaging techniques, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT), are significantly transforming the radiopharmaceuticals market by enabling enhanced visualization of radiopharmaceutical distribution and effectiveness. These innovations allow clinicians to obtain detailed, three-dimensional images of biological processes in real-time, improving the accuracy of diagnoses and treatment planning. For instance, the development of novel tracers for PET imaging, such as 18F-fluorodeoxyglucose (FDG), has revolutionized cancer diagnostics by highlighting metabolic activity in tumors, facilitating early detection and monitoring of treatment response. Furthermore, advancements in hybrid imaging systems that combine PET or SPECT with computed tomography (CT) provide complementary anatomical information, leading to more precise localization of lesions. This synergy enhances the ability to differentiate between benign and malignant tissues, ultimately guiding more effective treatment strategies. As these imaging techniques continue to evolve, they will further broaden the opportunies in the radiopharmaceutical market.

• Rising Expenditure on Research and Development (R&D)

The rising expenditure on research and development (R&D) in the radiopharmaceuticals sector presents significant market opportunities for companies and investors alike. With increasing investments, pharmaceutical firms are focusing on developing novel radiopharmaceuticals that can offer targeted treatment and improved diagnostic capabilities. Notably, companies such as Siemens Healthineers and GE Healthcare are ramping up their R&D efforts to enhance existing products and develop innovative solutions that meet clinical demands. For instance, Siemens Healthineers recently introduced a new PET radiopharmaceutical, aimed at improving the detection of tumors and guiding personalized treatment plans. Furthermore, collaborations between pharmaceutical companies and academic institutions are also intensifying, fostering innovation and accelerating the development of novel therapies. This rising focus on R&D opens up new avenues for market expansion and enhances patient outcomes through better-targeted therapies.

Restraints/Challenges

• High Production and Operational Cost

High production and operational costs are a significant barrier in the radiopharmaceuticals market due to the specialized infrastructure required for handling radioactive materials. Manufacturing radiopharmaceuticals involves setting up facilities equipped with advanced safety measures to prevent contamination and ensure the proper handling of isotopes. Such facilities must adhere to stringent regulatory standards, which increase the cost of production. In addition, the production process itself is complex, often requiring the use of cyclotrons or nuclear reactors to generate isotopes, further driving up operational expenses. For instance, the production of Lutetium-177 (Lu-177), a key isotope used in radioligand therapies for cancer treatment, requires highly controlled environments to maintain purity and potency. These high costs can limit the accessibility of these advanced treatments, especially in regions with limited healthcare funding or infrastructure, hampering the overall growth of the marekt.

• Stringent Regulations for Radiopharmaceuticals

Radiopharmaceuticals are compounds utilized for diagnosing specific medical conditions or treating certain diseases; however, varying government regulations for launching these products can significantly restrain market growth. Each country has its own set of regulations and distinct regulatory bodies overseeing these procedures, leading to stringent regulatory and product approval policies that may impede the global radiopharmaceuticals market. While these strict regulations are essential for maintaining industry integrity, ensuring product reliability, and building consumer trust, they complicate the development process. Gaining approval for a new drug involves several stages of investment and testing, each with specific regulatory requirements. Organizations conducting trials must adhere to the necessary documentation mandated by the relevant regulatory authority in their respective countries, ensuring compliance with local policies. Nonetheless, the rigorous regulatory framework governing the market for radiopharmaceuticals can hinder growth, and the potential withdrawal of drugs due to complex regulations could negatively affect market dynamics, ultimately restraining market expansion.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Radiopharmaceuticals Market Scope

The market is segmented on the basis of type, application, source, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Diagnostic Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals

Application

• Diagnostic
• Therapeutic

Source

• Nuclear Reactors
• Cyclotrons

End User

• Hospitals
• Diagnostic Centers
• Cancer Research Institutes
• Ambulatory Surgical Centers
• Others

Radiopharmaceuticals Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, application, source, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the global radiopharmaceuticals market, primarily driven by significant investments in the healthcare sector that are projected to stimulate market expansion. Within this region, the United States is expected to take the lead, largely due to its rapid technological advancements in healthcare solutions and innovative treatment options. In addition, the growing emphasis on early disease detection and personalized medicine in the U.S. further enhances the demand for radiopharmaceuticals, contributing to the region's dominance in this market.

Germany is projected to lead the European radiopharmaceuticals market, driven by a growing demand from emerging markets within the region. This rise in demand is further supported by the country's strong emphasis on research and development, which fosters innovation and enhances product offerings. In addition, Germany's well-established healthcare infrastructure and regulatory framework contribute to an environment conducive to the growth and expansion of the radiopharmaceutical industry.

China is anticipated to take the lead in the Asia-Pacific radiopharmaceuticals market, fueled by a growing preference among consumers for advanced technological processes in healthcare. This shift is driven by increased awareness of the benefits of innovative medical solutions and the rapid adoption of cutting-edge technologies. Furthermore, China's significant investments in healthcare infrastructure and research are enhancing its capabilities, positioning the country as a frontrunner in the development and application of radiopharmaceuticals across the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Radiopharmaceuticals Market Share

Le paysage concurrentiel du marché fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Les leaders du marché des produits radiopharmaceutiques opérant sur le marché sont :

• Cardinal Health (États-Unis)
• Advanced Accelerator Applications, une société Novartis (France)
• Lantheus (États-Unis)
• Curium (France)
• GE HealthCare (États-Unis)
• Jubilant Radiopharma, une société pharmaceutique Jubilant (Inde)
• Société chinoise d'isotopes et de radiations (Chine)
• Siemens Healthcare GmbH (Allemagne)
• Bracco (Italie)
• NTP (Afrique du Sud)
• Eckert & Ziegler (Allemagne)
• SHINE Technologies, LLC (États-Unis)
• Eczacıbaşı-Monrol (Turquie)
• IBA Worldwide (Belgique)
• Solutions médicales mondiales (États-Unis)
• BWX Technologies, Inc. (États-Unis)
• Institut des Isotopes (Hongrie)
• Coquí Radiopharmaceuticals Corp. (États-Unis)
• Evergreen Theragnostics, Inc. (États-Unis)
• Isotope JSC (Russie)
• PharmaLogic Holdings Corp. (États-Unis)

Dernières évolutions sur le marché des produits radiopharmaceutiques

• En mars 2024, Ariceum Therapeutics a lancé un laboratoire radiopharmaceutique à Berlin, qui facilitera la recherche et le développement internes de ses futurs candidats au pipeline
• En mars 2024, Ratio Therapeutics Inc. a annoncé un accord de fabrication élargi avec PharmaLogic, une organisation de développement et de fabrication sous contrat (CDMO) de premier plan spécialisée dans les produits radiopharmaceutiques. Cette collaboration vise à accélérer la production et la mise sur le marché des radiothérapies avancées de Ratio, en particulier son candidat ciblant la protéine d'activation des fibroblastes (FAP)
• En mars 2024, Telix Pharmaceuticals a finalisé l'acquisition d'ARTMS Inc. pour un montant pouvant atteindre 82 millions USD, renforçant ainsi ses capacités dans le domaine des produits radiopharmaceutiques. L'acquisition a donné accès à une technologie de production d'isotopes de pointe, à une usine de fabrication et à un stock de métaux rares ultra-purs, renforçant ainsi la position de Telix dans le secteur
• En février 2024, Bayer a renforcé sa collaboration avec PanTera en obtenant de l'actinium-225 pour le développement de produits radiopharmaceutiques innovants. Ce partenariat a représenté le premier engagement de PanTera avec une grande société pharmaceutique, initiant la fourniture d'essais cliniques au cours du second semestre de l'année
• En mai 2023, IBA a dévoilé AKURACY, une solution intégrée pour l'imagerie cardiaque TEP, lors de la réunion de l'EACVI à Barcelone. La société a souligné qu'il s'agissait d'une solution unique pour l'imagerie de perfusion myocardique TEP

SKU-7373